Hybrid inorganic-organic capsules for eficient intracellular delivery of novel siRNAs against influenza A (H1N1) virus infection

Alexander S. Timin, Albert R. Muslimov, Aleksandra V. Petrova, Kirill V. Lepik, Maria V. Okilova, Andrey V. Vasin, Boris V. Afanasyev, Gleb B. Sukhorukov

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The implementation of RNAi technology into the clinical practice has been significantly postponing due to the issues regarding to the delivery of naked siRNA predominantly to target cells. Here we report the approach to enhance the eficiency of siRNA delivery by encapsulating the siRNA into new carrier systems which are obtained via the combination of widely used layer-by-layer technique and in situ modification by sol-gel chemistry. We used three types of siRNAs (NP-717, NP-1155 and NP-1496) in encapsulated form as new therapeutic agents against H1N1 influenza virus infection. By employing the hybrid microcontainers for the siRNA encapsulation we demonstrate the reduction of viral nucleoprotein (NP) level and inhibition of influenza virus production in infected cell lines (MDCK and A549). The obtained hybrid carriers based on assembled biodegradable polyelectrolytes and solgel coating possess several advantages such as a high cell uptake eficiency, low toxicity, eficient intracellular delivery of siRNAs and the protection of siRNAs from premature degradation before reaching the target cells. These findings underpin a great potential of versatile microencapsulation technology for the development of anti-viral RNAi delivery systems against influenza virus infection.

Original languageEnglish
Article number102
JournalScientific Reports
Volume7
Issue number1
DOIs
Publication statusPublished - 2017

Fingerprint

H1N1 Subtype Influenza A Virus
Nucleoproteins
Influenza A virus
Virus Diseases
Small Interfering RNA
Capsules
Orthomyxoviridae
RNA Interference
Technology
Drug Compounding
Polymethyl Methacrylate
Gels
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

Hybrid inorganic-organic capsules for eficient intracellular delivery of novel siRNAs against influenza A (H1N1) virus infection. / Timin, Alexander S.; Muslimov, Albert R.; Petrova, Aleksandra V.; Lepik, Kirill V.; Okilova, Maria V.; Vasin, Andrey V.; Afanasyev, Boris V.; Sukhorukov, Gleb B.

In: Scientific Reports, Vol. 7, No. 1, 102, 2017.

Research output: Contribution to journalArticle

Timin, Alexander S. ; Muslimov, Albert R. ; Petrova, Aleksandra V. ; Lepik, Kirill V. ; Okilova, Maria V. ; Vasin, Andrey V. ; Afanasyev, Boris V. ; Sukhorukov, Gleb B. / Hybrid inorganic-organic capsules for eficient intracellular delivery of novel siRNAs against influenza A (H1N1) virus infection. In: Scientific Reports. 2017 ; Vol. 7, No. 1.
@article{ed5b360717a84debacf5f326f1fcfffa,
title = "Hybrid inorganic-organic capsules for eficient intracellular delivery of novel siRNAs against influenza A (H1N1) virus infection",
abstract = "The implementation of RNAi technology into the clinical practice has been significantly postponing due to the issues regarding to the delivery of naked siRNA predominantly to target cells. Here we report the approach to enhance the eficiency of siRNA delivery by encapsulating the siRNA into new carrier systems which are obtained via the combination of widely used layer-by-layer technique and in situ modification by sol-gel chemistry. We used three types of siRNAs (NP-717, NP-1155 and NP-1496) in encapsulated form as new therapeutic agents against H1N1 influenza virus infection. By employing the hybrid microcontainers for the siRNA encapsulation we demonstrate the reduction of viral nucleoprotein (NP) level and inhibition of influenza virus production in infected cell lines (MDCK and A549). The obtained hybrid carriers based on assembled biodegradable polyelectrolytes and solgel coating possess several advantages such as a high cell uptake eficiency, low toxicity, eficient intracellular delivery of siRNAs and the protection of siRNAs from premature degradation before reaching the target cells. These findings underpin a great potential of versatile microencapsulation technology for the development of anti-viral RNAi delivery systems against influenza virus infection.",
author = "Timin, {Alexander S.} and Muslimov, {Albert R.} and Petrova, {Aleksandra V.} and Lepik, {Kirill V.} and Okilova, {Maria V.} and Vasin, {Andrey V.} and Afanasyev, {Boris V.} and Sukhorukov, {Gleb B.}",
year = "2017",
doi = "10.1038/s41598-017-00200-0",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Hybrid inorganic-organic capsules for eficient intracellular delivery of novel siRNAs against influenza A (H1N1) virus infection

AU - Timin, Alexander S.

AU - Muslimov, Albert R.

AU - Petrova, Aleksandra V.

AU - Lepik, Kirill V.

AU - Okilova, Maria V.

AU - Vasin, Andrey V.

AU - Afanasyev, Boris V.

AU - Sukhorukov, Gleb B.

PY - 2017

Y1 - 2017

N2 - The implementation of RNAi technology into the clinical practice has been significantly postponing due to the issues regarding to the delivery of naked siRNA predominantly to target cells. Here we report the approach to enhance the eficiency of siRNA delivery by encapsulating the siRNA into new carrier systems which are obtained via the combination of widely used layer-by-layer technique and in situ modification by sol-gel chemistry. We used three types of siRNAs (NP-717, NP-1155 and NP-1496) in encapsulated form as new therapeutic agents against H1N1 influenza virus infection. By employing the hybrid microcontainers for the siRNA encapsulation we demonstrate the reduction of viral nucleoprotein (NP) level and inhibition of influenza virus production in infected cell lines (MDCK and A549). The obtained hybrid carriers based on assembled biodegradable polyelectrolytes and solgel coating possess several advantages such as a high cell uptake eficiency, low toxicity, eficient intracellular delivery of siRNAs and the protection of siRNAs from premature degradation before reaching the target cells. These findings underpin a great potential of versatile microencapsulation technology for the development of anti-viral RNAi delivery systems against influenza virus infection.

AB - The implementation of RNAi technology into the clinical practice has been significantly postponing due to the issues regarding to the delivery of naked siRNA predominantly to target cells. Here we report the approach to enhance the eficiency of siRNA delivery by encapsulating the siRNA into new carrier systems which are obtained via the combination of widely used layer-by-layer technique and in situ modification by sol-gel chemistry. We used three types of siRNAs (NP-717, NP-1155 and NP-1496) in encapsulated form as new therapeutic agents against H1N1 influenza virus infection. By employing the hybrid microcontainers for the siRNA encapsulation we demonstrate the reduction of viral nucleoprotein (NP) level and inhibition of influenza virus production in infected cell lines (MDCK and A549). The obtained hybrid carriers based on assembled biodegradable polyelectrolytes and solgel coating possess several advantages such as a high cell uptake eficiency, low toxicity, eficient intracellular delivery of siRNAs and the protection of siRNAs from premature degradation before reaching the target cells. These findings underpin a great potential of versatile microencapsulation technology for the development of anti-viral RNAi delivery systems against influenza virus infection.

UR - http://www.scopus.com/inward/record.url?scp=85018962380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018962380&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-00200-0

DO - 10.1038/s41598-017-00200-0

M3 - Article

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 102

ER -